ArcanaBio Secures Funding from BioInnovation Institute to Revolutionize Healthcare with Novel Ultra-Fast Liquid Biopsy Technology

ArcanaBio joins BII’s Deep Tech Lab Quantum – an initiative of the Novo Nordisk Foundation to support world-class innovations in quantum science

COPENHAGEN, Denmark, September 9, 2024–(BUSINESS WIRE)–ArcanaBio, a pioneering biotech company, is proud to announce that it has been selected for funding by the Danish BioInnovation Institute (BII), supported by the Novo Nordisk Foundation. ArcanaBio will join BII’s Deep Tech Lab – Quantum program in Copenhagen starting in September 2024.

“We are honored to receive funding and be selected to participate in this prestigious quantum initiative,” said Kristjan Gunnarsson, CEO of ArcanaBio. “We are at the forefront of a new biosensor revolution with a patent-pending, label-free detection technology that has long been a sought-after advancement in proteomics. Our new platform has the potential to enable testing laboratories to offer a broader range of biomarker services at a lower cost and to empower individuals to proactively monitor their health by integrating frequent, reference-quality testing into their lives.”

“The goal here is to rethink diagnostics. Building a new capability to track proteome dynamics can provide powerful real-time and predictive insights into health status, disease progression and epidemiology,” said Daniel Oskarsson, CTO of ArcanaBio. “Ultimately, this can serve as an enabler of preventive healthcare — a solution to the challenge of rising societal costs.”

ArcanaBio’s innovative label-free liquid biopsy solution uses novel nanophotonics technology combined with artificial intelligence (AI) to enable faster, cheaper, and higher frequency protein characterization and enable reference-quality diagnostics for home use.

About ArcanaBio

ArcanaBio is a leading biotech company focused on developing next-generation diagnostic technologies that are both fast and accessible. Now part of the BioInnovation Institute’s Deep Tech Lab – Quantum program, ArcanaBio leverages Denmark’s global leadership in quantum technology. With a focus on nanophotonics and biosensors, ArcanaBio aims to bring laboratory testing into everyday settings, empowering individuals to take charge of their health. For more information, visit www.arcanabio.com.

About BioInnovation Institute

The BioInnovation Institute (BII), an initiative of the Novo Nordisk Foundation, is a non-profit international entrepreneurial foundation dedicated to accelerating world-class innovations in life sciences. The Deep Tech Lab – Quantum, supported by BII, is Denmark’s official NATO DIANA accelerator site, leveraging the country’s leadership in quantum science to stimulate dual-use innovations in the life science and defense industries. For more information, visit bii.dk.

The story continues

View the source version on businesswire.com: https://www.businesswire.com/news/home/20240908214770/en/

Contacts

Kristjan Gunnarsson
CEO, ArcanaBio
Ole Maaløes Vej 3
2200 Copenhagen
Denmark

Telephone: +45 36 99 12 60
Email address: [email protected]